drugset / Trial / NCT00641979

New Nasal Applicator / New Formulation - User Study

NCT00641979

Phase 2 Completed 200 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).

Timeline

Start
2002-04
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule Intranasal